Plain-English translation of NCT07619092 on ClinicalTrials.gov ↗ · Source last updated ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing , a medication that reverses the effects of sedatives, during electroconvulsive therapy (ECT) — a treatment for severe depression where controlled seizures are triggered under anesthesia. The study wants to see if using allows patients to continue taking their regular sedative medications up until treatment, rather than stopping them the day before, and whether this approach helps protect thinking and memory.
Electroconvulsive therapy is very effective for severe depression, but it can affect memory and thinking. Patients typically stop taking sedative medications before treatment, which can cause anxiety and withdrawal symptoms. This study is exploring whether the medication can help patients stay on their regular sedatives, potentially reducing anxiety and protecting brain function during therapy.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of two groups: one group continues their regular sedative medications and receives the reversal medication during treatment, while the other group stops their sedatives the day before. Throughout your electroconvulsive therapy sessions, you'll complete thinking and memory tests, answer questions about depression symptoms and anxiety, and have brain imaging scans. The study tracks how well you recover and how your thinking and memory are affected over time.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Denmark